Jaguar Health, Inc. (JAGX)

0,2932 +0,0682 (+30,31 %) À la clôture : 04:00PM EDT

Jaguar Health, Inc.

200 Pine Street
Suite 400
San Francisco, CA 94104
United States
415 371 8300
https://jaguar.health

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 49

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Ms. Lisa A. Conte	Founder, CEO, President & Director	610,66k	S.O.	1959
Dr. Pravin R. Chaturvedi Ph.D.	Chief Scientific Officer & Chair of Scientific Advisory Board	517,91k	S.O.	1963
Dr. Steven R. King Ph.D.	Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary	406,4k	S.O.	1958
Ms. Carol R. Lizak M.B.A.	Chief Financial Officer	S.O.	S.O.	1964
Mr. Peter Hodge	Senior Director of Investor Relations, Business Development & Special Events	S.O.	S.O.	S.O.
Dr. Karen J. Brunke Ph.D.	Executive VP of Corporate & Business Development	S.O.	S.O.	1953
Mr. David Sesin	Chief Manufacturing Officer	S.O.	S.O.	S.O.
Mr. Ian H. Wendt M.B.A.	Chief Commercial Officer	441,31k	S.O.	1968
Dr. Massimo Radaelli M.B.A., Ph.D.	President of Jaguar International	S.O.	S.O.	1958
Ms. Catherine Miller Collis	Senior Vice President of Growth Strategy	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Jaguar Health, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.